Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein
- PMID: 8300410
- DOI: 10.1016/0198-8859(93)90508-x
Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein
Abstract
Experiments were carried out to determine whether complexes between MHC class I molecules and synthetic peptides are representative of those formed under more physiologically relevant conditions, with peptides derived intracellularly from processed antigens. Lysis of cells sensitized with exogenously provided and endogenously generated peptide analogues of the optimal nonameric peptide 58-66 (GILGFVFTL; derived from the influenza virus matrix protein) was compared. Endogenous loading was accomplished by expressing minigene DNA coding for alanine-substituted analogues of peptide 58-66 in HLA-A2-positive cells. Susceptibility to lysis by HLA-A2-restricted, peptide-specific cytotoxic lymphocytes was compared with lysis of cells sensitized with the same synthetic peptides. Although results were quite comparable, differences were observed. The endogenously presented analogues 58-66L60A, G61A, T65A, and L66A were recognized more efficiently than the corresponding exogenously presented analogues. This difference in recognition was most striking for peptide 58-66G61A. These results indicate the need for caution in using synthetic peptides in defining peptide binding motifs. Additional experiments with endogenously expressed analogues of 58-66 with substitutions other than alanine were carried out to define the interaction between this peptide and HLA-A2. Results are compatible with the interpretation that residues 58, 59, and 60 interact with pockets A, B, and D, respectively, in the HLA-A2 binding groove and that these interactions contribute to peptide binding.
Similar articles
-
Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes.Nature. 1989 Nov 23;342(6248):443-6. doi: 10.1038/342443a0. Nature. 1989. PMID: 2479838
-
Endogenous loading of HLA-A2 molecules with an analog of the influenza virus matrix protein-derived peptide and its inhibition by an exogenous peptide antagonist.J Immunol. 1992 Jan 1;148(1):7-12. J Immunol. 1992. PMID: 1727876
-
Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes.Eur J Immunol. 1992 Apr;22(4):903-7. doi: 10.1002/eji.1830220404. Eur J Immunol. 1992. PMID: 1372560
-
Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition.J Immunol. 1995 Feb 1;154(3):1088-96. J Immunol. 1995. PMID: 7822785
-
Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells.J Immunol. 1993 Mar 1;150(5):1763-71. J Immunol. 1993. PMID: 7679694
Cited by
-
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d. J Immunother. 2011. PMID: 21904219 Free PMC article.
-
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.Cancer Immunol Immunother. 2011 Jun;60(6):781-92. doi: 10.1007/s00262-011-0987-5. Epub 2011 Feb 25. Cancer Immunol Immunother. 2011. PMID: 21350948 Free PMC article.
-
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.J Clin Immunol. 2003 Jan;23(1):62-72. doi: 10.1023/a:1021904432489. J Clin Immunol. 2003. PMID: 12645861 Clinical Trial.
-
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6. Cancer Immunol Immunother. 2010. PMID: 20140431 Free PMC article.
-
Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals.Cancer Immunol Immunother. 2007 Jul;56(7):1047-63. doi: 10.1007/s00262-006-0246-3. Epub 2006 Nov 24. Cancer Immunol Immunother. 2007. PMID: 17124584 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials